Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Travere Therapeutics Inc
(NQ:
TVTX
)
8.680
-0.100 (-1.14%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Travere Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
The Latest Analyst Ratings for Travere Therapeutics
April 17, 2023
Via
Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 13, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Additional Data From Travere Therapeutics' Kidney Disease Candidate Reinforce Efficacy, Supporting Ongoing Launch
April 03, 2023
Via
Benzinga
Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023
April 01, 2023
FILSPARI demonstrated a statistically significant, rapid, and sustained decline of proteinuria compared to the active control
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Could an FDA Approval Send This Stock Flying?
March 01, 2023
Is now the time to load up on this struggling stock?
Via
The Motley Fool
Travere Therapeutics's Return On Capital Employed Overview
February 28, 2023
Via
Benzinga
Why Travere Therapeutics Stock Bolted Higher This Week
February 23, 2023
A high-value regulatory approval lit a fire underneath the biotech's shares this week.
Via
The Motley Fool
Travere Therapeutics to Present at Upcoming Investor Conferences
March 28, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
3 Up-and-Coming Growth Stocks to Buy Right Now
March 25, 2023
These companies are small now but could grow much larger over time.
Via
The Motley Fool
Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023
March 23, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
3 Supercharged Stocks Near 52-Week Highs That Could Keep Climbing
March 19, 2023
The high-flyers have soared to new heights and further gains could be up ahead.
Via
The Motley Fool
Travere Therapeutics's Earnings Outlook
February 22, 2023
Via
Benzinga
What 10 Analyst Ratings Have To Say About Travere Therapeutics
February 22, 2023
Via
Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 14, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 44th Annual Meeting and the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting 2023
March 14, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
March 03, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Analyst Views Multiple Opportunities For Chinook To Thrive In Emerging Renal Markets, Sees More Than 100% Upside
March 01, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023
March 01, 2023
Via
Benzinga
Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
February 28, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Announces Proposed Public Offering of Common Stock
February 27, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
February 23, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 21, 2023
Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023.
Via
Benzinga
Earnings Scheduled For February 23, 2023
February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
February 21, 2023
Via
Benzinga
Manitowoc, Helix Energy Solutions, JELD-WEN Holding And Other Big Stocks Moving Higher On Tuesday
February 21, 2023
U.S. stocks traded lower, with the Dow Jones dropping around 450 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
February 21, 2023
Via
Benzinga
Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment
February 21, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
February 20, 2023
Via
Benzinga
Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
February 17, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Travere Therapeutics Announces FDA Accelerated Approval of FILSPARITM (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
February 17, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.